CON: Blood Pressure Treatment Goal for Patients With Diabetes Should Be <130/80 mm Hg
Key result
Evidence from prospective trials shows that while reducing systolic blood pressure below 140 mm Hg reduces cardiovascular events in diabetes, lowering it below 130 mm Hg provides no additional overall cardiovascular benefit.
Why the study?
Does intensive blood pressure lowering to <130/80 mm Hg reduce cardiovascular risk and CKD progression in patients with diabetes or CKD?
Population
Patients with diabetes or chronic kidney disease (CKD)
Comparison
Intensive blood pressure lowering to a goal of… vs Conventional blood pressure control
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Does not support universal <130/80 mm Hg target for overall CV benefit in diabetes or CKD; leaves open stroke-specific benefit and needs prospective trials.
Key Points
- To evaluate whether prospective randomized clinical trial evidence supports blood pressure targets below 130/80 mm Hg for reducing cardiovascular risk and slowing chronic kidney disease progression in patients with diabetes.
- Reviewed prospective randomized outcome trials comparing intensive versus standard blood pressure targets in diabetes and renal disease, including ACCORD, ABCD, UKPDS, MDRD, and AASK.
- Evaluated cardiovascular composite endpoints, stroke incidence, medication side effects, and renal disease progression across clinical trial cohorts and post hoc analyses.
- In the ACCORD trial, achieving a sustained 14 mm Hg systolic blood pressure separation (119 mm Hg vs 133 mm Hg) over 4 years showed no significant benefit on primary cardiovascular events, with lower stroke risk offset by elevated medication adverse effects.
- Post hoc analyses from ONTARGET and INVEST demonstrated a loss of cardiovascular risk reduction at systolic levels under 130 mm Hg and increased cardiovascular events below 115 mm Hg in coronary disease patients.
- Renal progression was not slowed by intensive blood pressure lowering in MDRD or AASK for overall cohorts, with benefits confined specifically to subgroups with baseline proteinuria exceeding 500 to 1000 mg/d.
Structured PICO
Does intensive blood pressure lowering to <130/80 mm Hg reduce cardiovascular risk and CKD progression in patients with diabetes or CKD?
P
Population
Patients with diabetes or chronic kidney disease (CKD)
I
Intervention
Intensive blood pressure lowering to a goal of <130/80 mm Hg
C
Comparator
Conventional blood pressure control (e.g., <140/90 mm Hg)
O
Outcome
Cardiovascular risk reduction and CKD progressionhard clinical
A universal blood pressure target of <130/80 mm Hg for patients with diabetes or CKD is not supported by robust prospective trial data for overall cardiovascular risk reduction, though it may reduce stroke risk.
Limitations
- Original recommendations for <130/80 mm Hg were based on retrospective data analyses rather than appropriately powered prospective outcome trials.
- No trial has achieved a mean office BP reading of <130/80 mm Hg based on a randomization scheme tied to outcomes.
Cite This Study
George L. Bakris (2011) conducted an editorial in Diabetes and Hypertension. Blood pressure target <130/80 mm Hg vs. Conventional blood pressure target (<140/90 mm Hg) was evaluated. Evidence from prospective trials shows that while reducing systolic blood pressure below 140 mm Hg reduces cardiovascular events in diabetes, lowering it below 130 mm Hg provides no additional overall cardiovascular benefit.